about
The risk of elevated prolactin levels in pediatric patients exposed to antipsychotics for the treatment of schizophrenia and schizophrenia spectrum disorders: protocol for a systematic review and meta-analysisAn animal model of emotional blunting in schizophrenia.Identification of ANKK1 rs1800497 variant in schizophrenia: new data and meta-analysis.The First Negative Allosteric Modulator for Dopamine D2 and D3 Receptors, SB269652 May Lead to a New Generation of Antipsychotic DrugsSchizophrenia gene expression profile reverted to normal levels by antipsychoticsCharacterization of atypical antipsychotic drugs by a late decrease of striatal alpha1 spectral power in the electropharmacogram of freely moving ratsBiological basis for cerebral dysfunction in schizophrenia in contrast with Alzheimer's disease.How have developments in molecular imaging techniques furthered schizophrenia research?Apolipoprotein D takes center stage in the stress response of the aging and degenerative brain.Progress toward advanced understanding of metabotropic glutamate receptors: structure, signaling and therapeutic indicationsHippocampal Pruning as a New Theory of Schizophrenia Etiopathogenesis.Model-based approaches to increase efficiency of drug development in schizophrenia: a can't miss opportunity.Effectiveness of rivastigmine on positive, negative, and cognitive symptoms of schizophrenia: a double-blind clinical trial.Schizophrenia and sleep disorders: links, risks, and management challenges
P2860
Q26996493-D97AF9BE-7A2C-48F6-AE24-6F85A3C796B4Q28471824-415A5DCE-FE47-4585-BE75-42C59AF0B94FQ30839452-13DB99C7-7389-45A3-A6A8-723B88E9F7EFQ33707895-AE59B0B0-F5F5-4C9E-B694-A6F12D115DCAQ35179019-19A3D518-71CF-4A46-9C76-DABE4A080E61Q36104894-E04642C2-0AF1-4E1F-9115-A033A9BDD2A8Q37541554-8C50939B-070B-469D-A432-590A74F70FFAQ37829639-0E153621-FEB1-4361-ADD5-8C312952916DQ38194683-16939D29-851F-42EF-A5D6-38921B5005EDQ38209092-269F2097-508E-4BD3-8207-6E2DFEFFFE1BQ38464009-3EA778C4-1477-4AA3-8722-B0F2B3C4C845Q39959170-7C3AA72B-1F19-4817-9CC2-9C7DEBB7640CQ41179447-0B83733B-DE19-4A3F-A443-39D5FA9B203EQ42364468-17CD3D24-2820-47EA-86DB-A4A52E3B04E6
P2860
description
2002 nî lūn-bûn
@nan
2002 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Dopamine and antipsychotic drug action revisited.
@ast
Dopamine and antipsychotic drug action revisited.
@en
Dopamine and antipsychotic drug action revisited.
@en-gb
type
label
Dopamine and antipsychotic drug action revisited.
@ast
Dopamine and antipsychotic drug action revisited.
@en
Dopamine and antipsychotic drug action revisited.
@en-gb
prefLabel
Dopamine and antipsychotic drug action revisited.
@ast
Dopamine and antipsychotic drug action revisited.
@en
Dopamine and antipsychotic drug action revisited.
@en-gb
P356
P1476
Dopamine and antipsychotic drug action revisited.
@en
P2093
P304
P356
10.1192/BJP.181.4.271
P407
P577
2002-10-01T00:00:00Z